Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations
ATLANTA--(BUSINESS WIRE)--#Biotech--Axion BioSystems vigorously refutes a recent filing by Agilent Technologies, Inc. (NYSE: A) claiming patent infringement and false advertising.
As a recognized biotechnology innovator and owner of numerous patents over 14 years, Axion BioSystems expects its competitors to respect its intellectual property rights, just as Axion respects the intellectual property rights of its competitors. But when competitors make allegations that are without merit, Axion must robustly defend itself.
At issue are Agilent Technologies, Inc.’s spurious allegations of false advertising and claims that certain of Axion’s live-cell analysis products infringe three Agilent patents. In rebuttal, Axion rejects any claims of patent infringement and stands by the technological capabilities of its products.
Axion is confident that it does not infringe Agilent’s patents and that those patents will ultimately be proven invalid. Axion looks forward to vindicating its rights in court and obtaining a successful outcome against Agilent. Axion BioSystems will continue to advance the frontiers of live-cell analysis as a market innovator to accelerate biomedical discoveries.
About Axion BioSystems
Axion BioSystems, Inc. is a leading life science company focused on next-generation live-cell analysis tools for biomedical research and drug discovery. With innovative systems that monitor complex cellular activity in real time without disturbing the underlying biology, Axion’s technology accelerates scientific discovery with streamlined workflows providing more complete datasets. Headquartered in Atlanta, Georgia, USA, the company has more than 180 employees worldwide. www.axionbiosystems.com
Vice President Marketing, Axion BioSystems